バーゼル、2026年4月24日 — ノバルティスは本日、世界保健機関（WHO）が体重2～5キログラムの新生児および低月齢乳児のために特別に開発された、世界初かつ唯一の抗マラリア薬であるCoartem ...
Q3 net sales grew +4% (cc ¹, +4% USD), with core operating income ¹ +10% (cc, +11% USD) Sales growth driven by priorit ...
MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...
“The clinically meaningful overall survival benefit observed in NATALEE underscores Kisqali as a standard of care for eligible patients and its foundational role in early breast cancer treatment,” ...
and simultaneously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress on June 3, 2026.²˒⁹ “People living with PMR need treatments that provide lasting remission, ...
HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence of clinical activity in ...
本資料は、ノバルティス（スイス・バーゼル）が2026年7月31日（現地時間）に発表したものを日本語に翻訳（要約）したもので、参考資料として提供するものです。資料の内容および解釈に ...
本資料は、ノバルティス（スイス・バーゼル）が2026年7月21日（現地時間）に発表したものを日本語に翻訳（要約）したもので、参考資料として提供するものです。資料の内容および解釈に ...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of ...
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III ...
Novartis’ commitment to kidney diseases Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results